357 related articles for article (PubMed ID: 18524866)
1. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
Tuffaha HW; Treish IM; Zaru L
J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
[TBL] [Abstract][Full Text] [Related]
2. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
3. Impact of primary prophylaxis on febrile neutropenia within community practices in the US.
Hershman D; Hurley D; Wong M; Morrison VA; Malin JL
J Med Econ; 2009 Sep; 12(3):203-10. PubMed ID: 19723018
[TBL] [Abstract][Full Text] [Related]
4. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
Timmer-Bonte JN; Tjan-Heijnen VC
Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
10. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
13. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
15. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
16. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia.
Gupta S; Singh PK; Bhatt ML; Pant MC; Gupta R; Negi MP
Biosci Trends; 2010 Oct; 4(5):273-8. PubMed ID: 21068482
[TBL] [Abstract][Full Text] [Related]
19. Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
